Navigation Links
Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
Date:12/10/2007

filed a New Drug Application (NDA) to FDA for the use of Genasense plus chemotherapy in patients with relapsed/refractory CLL in December 2005. In December 2006, FDA issued a non-approvable decision on this NDA. Genta has appealed this decision using FDA's established Dispute Resolution Process. An initial review of this appeal by FDA's Office of New Drugs declined to overturn the earlier decision. Genta has appealed the non-approvable decision to CDER, which is currently pending.

About Chronic Lymphocytic Leukemia

CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells. Eventually, these problems may cause life-threatening complications, such as overwhelming infections and fatal bleeding. More information about CLL can be accessed at the website for the Lymphoma Research Foundation at: http://www.lymphoma.org.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  The board of directors of AbbVie Inc. (NYSE: ... of $0.42 per share.  The cash ... record at the close of business on Oct. 15, ... research-based biopharmaceutical company formed in 2013 following separation from ... dedicated people and unique approach to innovation to develop ...
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 Larry J. Merlo , President ... will speak before the National Press Club in ... recent move to stop selling tobacco products and its leadership ... health. "Dramatic changes in our health care system ... government," Merlo has said. "CVS Health has a truly unique ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
(Date:9/20/2014)... "As a nurse, patients always ask me how ... from Tamaqua, Pa. "The reason that they cannot tell is ... chairs. My invention enables them to check oxygen levels on ... make it easier to monitor the contents of an oxygen ... tank is low. It allows changeovers to be performed under ...
(Date:9/20/2014)... Los Angeles, CA (PRWEB) September 20, 2014 ... power score of 3.1 out of 5, indicating a ... research firm IBISWorld, this score reflects current and future ... negotiate from historically high prices. Other factors that negatively ... volatility in demand for construction and the moderate switching ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Final Cut ... announced the release of the Information theme for FCPX filmmakers. ... use to describe the Information theme,” says Christina Austin, CEO ... to look so professional.” , Information features easy to use ... parameters of the environment. Change the background color, color of ...
(Date:9/20/2014)... 2014 The first federal bellwether trial ... its third week in the U.S. District Court, Northern ... documents indicate that the week opened in the ... a DePuy Orthopaedics vice president, who discussed the clinical ... Pinnacle hip replacement. According to Reuters, the executive stated ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... Susan Desmond-Hellmann, MD, MPH, will be inducted today ... alongside some of the world,s other most distinguished ... a renowned oncologist and biotechnology leader who now ... was among five members of the 210 new ...
... technique appears to offer quick and effective relief for ... cancer, researchers reported at the 35th Congress of the ... Many patients with multiple myeloma, or those whose cancer ... fractures in their spine. This is partly because the ...
... Diseases, part of the National Institutes of Health, has ... Virginia Bioinformatics Institute (VBI) and collaborators to determine how ... of the gut. The funding will be used to ... to gut pathogens. "The Center for Modeling Immunity ...
... HealthDay Reporter , FRIDAY, Oct. 8 (HealthDay News) -- Researchers ... may double the odds that a child will develop a ... The study authors aren,t calling for an end to childhood ... such as pneumonia and broken bones. And the study doesn,t ...
... treatment has shown encouraging activity as a first-line therapy ... Congress of the European Society for Medical Oncology (ESMO) ... MD, Mayo Clinic in Florida, presented the results of ... a first-line treatment for metastatic breast cancer. ...
... the European Health Award 2010 handed to the Chronic Disease ... 6 9 October 2010. The ESC was instrumental ... health professionals. The stepping stone was a policy conference organised ... together 10 European health organisations. In just a year, the ...
Cached Medicine News:Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 2Health News:UCSF Chancellor inducted into Academy of Arts and Sciences 3Health News:Surgical technique relieves painful spine fractures in patients with metastatic cancer 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 2Health News:Virginia Bioinformatics Institute to model immune responses to gut pathogens 3Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 2Health News:3 or More X-Rays May Raise Leukemia Risk Among Kids: Study 3Health News:Targeted therapy promising for HER2-positive metastatic breast cancer 2Health News:Chronic Disease Alliance receives European Health Award 2010 2Health News:Chronic Disease Alliance receives European Health Award 2010 3Health News:Chronic Disease Alliance receives European Health Award 2010 4
... Freedom® CMC ThumbFit™ reduces joint ... low-profile splint is remarkably comfortable and ... adjust.,Pamela Kirby, OTR/L, CHT and Robert ... the splint together in response to ...
... Blue Line ThumStay offers thumb and wrist ... soft, breathable foam. Lightweight stays provide firm ... can easily be contoured for proper positioning ... deQuervain's tenosynovitis, tendinitis, CMC joint arthritis, and ...
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
... orthosis is designed to comfortably restrict motion ... the hand in a neutral position. It ... thermoplastic whose unique characteristics offer durable performance ... rigid cast-like immobilization of the wrist, hand, ...
Medicine Products: